Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 3/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 10/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 6/20 | 0.44 |
| ▸ | FOS | P01100 | 2/20 | 0.41 |
| ▸ | TTR | P02766 | 2/20 | 0.41 |
| ▸ | JUN | P05412 | 2/20 | 0.41 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.41 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.41 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.41 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | ESR1 | P03372 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | RECQL | P46063 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6611829 | 0.87 | PDE2A (0.47) | PDE2AEPHX2CACNA1HHCRTR1HCRTR2 | |
| SCHEMBL20061666 | 0.84 | PDE2A (0.42) | PDE2AEPHX2ALOX15CACNA1HHCRTR1 | |
| SCHEMBL20128505 | 0.83 | ALOX15 (0.43) | ALOX15ALOX12FOSTTRJUN | |
| SCHEMBL18181376 | 0.83 | PDE2A (0.43) | PDE2AEPHX2CACNA1HHCRTR1HCRTR2 | |
| SCHEMBL20061670 | 0.82 | ALOX15 (0.60) | ALOX15ALOX12FOSTTRJUN | |
| SCHEMBL20132766 | 0.81 | ALOX5AP (0.36) | PDE2AEPHX2ALOX15CACNA1HHCRTR1 | |
| SCHEMBL6600311 | 0.81 | TP53 (0.45) | PDE2AEPHX2CACNA1HTP53HCRTR1 | |
| SCHEMBL18174275 | 0.80 | EPHX2 (0.50) | PDE2AEPHX2CACNA1HPPARG | |
| SCHEMBL20128512 | 0.80 | EPHX2 (0.50) | PDE2AEPHX2CACNA1H | |
| SCHEMBL18174185 | 0.80 | EPHX2 (0.50) | PDE2AEPHX2CACNA1HPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10428065-B2 | Isoxazolyl substituted imidazopyridines | CELLCENTRIC LTD (GB) | 2019-10-01 | — | — | US | disclosed |
| US-20180127402-A1 | ISOXAZOLYL SUBSTITUTED BENZIMIDAZOLES | CELLCENTRIC LTD (GB) | 2018-05-10 | — | — | US | disclosed |
| US-20180127402-A1 | ISOXAZOLYL SUBSTITUTED BENZIMIDAZOLES | CELLCENTRIC LTD (GB) | 2018-05-10 | — | — | US | disclosed |
| US-20180105519-A1 | ISOXAZOLYL SUBSTITUTED IMIDAZOPYRIDINES | CELLCENTRIC LTD (GB) | 2018-04-19 | — | — | US | disclosed |
| US-20180105519-A1 | ISOXAZOLYL SUBSTITUTED IMIDAZOPYRIDINES | CELLCENTRIC LTD (GB) | 2018-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180105519-A1 | ISOXAZOLYL SUBSTITUTED IMIDAZOPYRIDINES | EP300, HDAC3, HDAC1 | PDE2A 3909/4885EPHX2 3301/4885ALOX15 4664/4885 |
| US-20180127402-A1 | ISOXAZOLYL SUBSTITUTED BENZIMIDAZOLES | EP300, HDAC3, HDAC1 | PDE2A 4039/4885EPHX2 3907/4885ALOX15 4701/4885 |
| US-10428065-B2 | Isoxazolyl substituted imidazopyridines | EP300, HDAC3, HDAC1 | PDE2A 3909/4885EPHX2 3301/4885ALOX15 4664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.